{"filings":[{"id":954204,"accession_number":"0001193125-26-264514","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","form_type":"8-K","filed_at":"2026-06-10T00:30:15+00:00","items":["5.02","5.07","7.01","9.01"],"status":"ready","headline":"Aldeyra Therapeutics Appoints Darlene Deptula-Hicks as New Director and Audit Committee Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Darlene Deptula-Hicks appointed Class III director and Audit Committee Chair on June 9, 2026.","Ms. Deptula-Hicks received an option to purchase 94,313 shares vesting over three years.","Annual meeting ratified BDO USA as auditor; advisory say-on-pay passed.","Todd C. Brady, M.D., Ph.D., re-elected as director with 23,026,101 votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":105561870.76023392,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92327,"accession_number":"0001193125-26-199157","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aldeyra provides reproxalap trial endpoint estimates and FDA stance in corporate overview","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Standardized treatment estimates and confidence intervals disclosed for reproxalap dry eye disease clinical trials primary endpoints.","Aldeyra summarizes its interpretations of FDA positions on primary endpoints and its own positions in the NDA.","Presentation is a voluntary Reg FD disclosure; no financial results or guidance included."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":105561870.76023392,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92326,"accession_number":"0001193125-26-164198","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","form_type":"8-K","filed_at":"2026-04-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Martin J. Joyce will not stand for re-election at 2026 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Martin J. Joyce notified Aldeyra on April 20, 2026 of his decision not to stand for re-election.","His term will expire at the upcoming 2026 annual meeting of stockholders.","The decision was not the result of any disagreement with Aldeyra."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":105561870.76023392,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92325,"accession_number":"0001193125-26-137984","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Aldeyra repays $15M Hercules loan, terminates credit facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Paid off $15M outstanding borrowings and terminated all commitments under Hercules Credit Facility on April 1, 2026.","Credit facility had maturity date of April 1, 2026; termination follows previously disclosed terms.","Cash, equivalents, and marketable securities as of Dec 31, 2025 expected to support operations into 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":105561870.76023392,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103100,"accession_number":"0001193125-26-109511","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA issues second Complete Response Letter for Aldeyra's reproxalap NDA; efficacy concerns cited","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CRL states 'lack of substantial evidence' and 'failed to demonstrate efficacy' for dry eye disease signs and symptoms.","No safety or manufacturing concerns identified; FDA did not recommend additional trials or confirmatory evidence.","Aldeyra intends to request Type A meeting within 30 days to determine next steps for approval.","Cash and marketable securities of $70M as of Dec 31, 2025 expected to fund operations into 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":105561870.76023392,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119340,"accession_number":"0001193125-25-338394","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","form_type":"8-K","filed_at":"2025-12-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Aldeyra CDO Stephen Machatha resigns; transition through March 2026 with $176K severance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chief Development Officer Stephen G. Machatha voluntarily resigns effective on/before March 31, 2026.","Machatha to remain employed through transition period to ensure smooth handoff.","Severance includes $88K lump sum (50% of 2025 bonus at 110% of target) plus another $88K on release.","No dispute with management cited as reason for departure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":105561870.76023392,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119339,"accession_number":"0001193125-25-319638","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Aldeyra: FDA extends reproxalap PDUFA to March 16, 2026 after requesting failed trial report","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["PDUFA target action date extended three months to March 16, 2026 from original Dec 16, 2025.","FDA requested CSR of dry eye field trial that missed primary endpoint; CSR submitted Dec 12 as major amendment.","FDA shared draft label in early December; Aldeyra responded; labeling and postmarketing plans expected by Feb 16, 2026.","No other specific issues or requests identified by FDA during review.","Field trial top-line results announced May 5, 2025; safety data previously submitted Aug 21, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":105561870.76023392,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119338,"accession_number":"0001193125-25-278804","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Aldeyra expands RASP platform to CNS diseases; reproxalap manufacturing inspections closed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ADX-248 preclinical results in Parkinson's & ALS models showed improved grip strength, balance, and CNS biomarkers.","FDA completed reproxalap drug substance and product facility inspections; closed with VAI designation, no further action.","Aldeyra expanded RASP platform to central nervous system diseases; ADX-248 is oral next-gen RASP modulator.","Reproxalap is a first-in-class investigational candidate for dry eye disease signs and symptoms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":105561870.76023392,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119337,"accession_number":"0001193125-25-252200","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aldeyra positive Phase 2 ADX-629 in alcohol-hepatitis; pipeline focuses on ADX-248/ADX-246; cash runway into H2 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ADX-629 Phase 2 trial in mild-to-moderate alcohol-associated hepatitis showed significant improvement in MELD score (P=0.001), triglycerides (P<0.0001), and CRP (P<0.0001).","Pipeline focused on next-generation RASP modulators ADX-248 (metabolic inflammation, IND 2026) and ADX-246 (dry AMD, IND 2026); ADX-629 development discontinued.","Cash runway extended into second half of 2027 due to pipeline prioritization.","No serious adverse events reported in the ADX-629 trial; drug was well tolerated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":105561870.76023392,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135908,"accession_number":"0000950170-25-109932","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","form_type":"8-K","filed_at":"2025-08-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aldeyra receives FDA Fast Track Designation for ADX-2191 in retinitis pigmentosa","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Fast Track Designation for ADX-2191 (methotrexate intravitreal injection) for retinitis pigmentosa.","No approved therapy exists for most forms of retinitis pigmentosa, which affects over 1 million people worldwide.","Fast Track complements prior Orphan Drug Designation; may allow rolling review or priority/accelerated approval.","Phase 2/3 trial of ADX-2191 in retinitis pigmentosa expected to start in 2025.","Phase 2 results (2023) showed improvements from baseline in retinal sensitivity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":105561870.76023392,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135907,"accession_number":"0001213900-25-064869","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","form_type":"8-K","filed_at":"2025-07-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA accepts Aldeyra's reproxalap NDA resubmission for dry eye disease; PDUFA Dec 16, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted for review the resubmitted NDA for topical ocular reproxalap, a first-in-class candidate for dry eye disease.","PDUFA target action date set for December 16, 2025.","Resubmission includes a single clinical trial that met primary endpoint of reducing ocular discomfort vs vehicle control.","Reproxalap is the only dry eye investigational therapy to show acute activity reducing ocular discomfort and redness in pivotal trials simulating disease flares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":105561870.76023392,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152898,"accession_number":"0001213900-25-058035","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Aldeyra receives FDA Special Protocol Assessment for ADX-2191 in primary vitreoretinal lymphoma","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["SPA agreement provides FDA alignment on clinical trial design for ADX-2191 (methotrexate injection) to treat PVRL, a rare and fatal cancer with no approved therapy.","Trial will randomize up to 20 patients 1:1 to a single intravitreal injection vs. eight injections; primary endpoint is cancer cell clearance at 30 days.","Trial expected to start H2 2025 and conclude in 2026; positive SPA may support NDA resubmission with one adequate and well-controlled study plus literature.","Prior NDA for ADX-2191 received a Complete Response Letter in June 2023 due to insufficient literature-based efficacy evidence.","ADX-2191 is a novel, vitreous-compatible methotrexate formulation designed for intraocular injection potentially reducing injection volume vs. compounded methotrexate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":105561870.76023392,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152897,"accession_number":"0001213900-25-054949","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aldeyra resubmits reproxalap NDA for dry eye disease after CRL, Phase 3 trial met primary endpoint","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Resubmitted NDA to FDA for topical ocular reproxalap to treat signs and symptoms of dry eye disease.","Earlier CRL in April 2025 cited potential methodological issues; new Phase 3 dry eye chamber trial achieved primary endpoint (P=0.002).","No notable baseline differences across treatment arms; mild transient instillation site discomfort was most common AE.","PDUFA goal: FDA acceptance decision within 30 days, review completion within 6 months of submission."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":105561870.76023392,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152896,"accession_number":"0000950170-25-084820","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Aldeyra shareholders elect directors, ratify BDO, approve executive pay at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Richard H. Douglas, Gary M. Phillips, and Neal S. Walker as Class II directors with over 21M votes each; broker non-votes ~18.7M.","Ratified BDO USA as independent auditor for FY2025 with 44.86M votes for, 0.65M against, 0.10M abstain.","Approved non-binding advisory vote on executive compensation with 18.85M for, 7.92M against, 0.18M abstain; broker non-votes 18.67M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":105561870.76023392,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152895,"accession_number":"0001193125-25-113275","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Aldeyra reproxalap meets primary endpoint in Phase 3 dry eye chamber trial; NDA resubmission planned mid-2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reproxalap statistically superior to vehicle on ocular discomfort (LS mean diff -6.5, P=0.002) in Phase 3 chamber trial (n=58 per arm).","No notable baseline differences across treatment arms; Aldeyra believes data address FDA CRL from April 2025.","NDA resubmission anticipated mid-2025 pending Type A meeting; review expected six months.","A recent field trial was numerically supportive but did not reach statistical significance; will be submitted as supportive.","No safety signals or treatment-related discontinuations; reproxalap well tolerated in over 2,900 patients studied."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":105561870.76023392,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152894,"accession_number":"0001213900-25-032947","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","form_type":"8-K","filed_at":"2025-04-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Aldeyra Therapeutics appoints Chip Clark to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["William (Chip) Clark elected as Class I director on April 17, 2025; term expires at 2027 annual meeting.","Board size increased to eight upon Clark's election.","Clark received option to purchase 76,760 shares at closing price on April 17, 2025, vesting over 3 years.","Annual director fee of $40,000 plus eligibility for annual option grant worth ~$130,000.","Clark is co-founder/CEO of Vibrant Biomedicines, former CEO of Genocea Biosciences."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":105561870.76023392,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152893,"accession_number":"0001193125-25-072424","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","form_type":"8-K","filed_at":"2025-04-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA issues Complete Response Letter for Aldeyra's reproxalap dry eye NDA; additional study required","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA CRL states reproxalap 'failed to demonstrate efficacy' in adequate studies; no safety or manufacturing issues.","Type A meeting expected within ~30 days; top-line data from ongoing chamber and field trials due Q2 2025.","Aldeyra plans NDA resubmission mid-2025 pending positive results and FDA discussions; review period expected 6 months.","Cash, equivalents, and marketable securities $101M as of Dec 31, 2024; 2025 trial costs ~$6M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":105561870.76023392,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188700,"accession_number":"0001213900-24-099333","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","form_type":"8-K","filed_at":"2024-11-18T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Aldeyra's reproxalap NDA accepted by FDA with April 2, 2025 PDUFA; expands AbbVie option deal","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted resubmitted NDA for reproxalap for dry eye disease; PDUFA date April 2, 2025.","Expanded option with AbbVie: upon exercise, AbbVie pays $100M upfront (less $6M fees) plus up to $300M milestones.","If option exercised, profit/loss split 60% AbbVie, 40% Aldeyra; Aldeyra pre-commercial costs 60% reimbursed by AbbVie.","Option exercise period amended to 10 business days after FDA approval of reproxalap for dry eye disease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":105561870.76023392,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188699,"accession_number":"0001213900-24-084844","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","form_type":"8-K","filed_at":"2024-10-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aldeyra resubmits reproxalap NDA for dry eye disease after positive Phase 3 trial","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Resubmission includes positive results from FDA-requested symptom trial.","Phase 3 dry eye chamber trial met primary endpoint (ocular discomfort, P=0.004).","If approved, reproxalap would be first chronic dry eye therapy with acute symptom and redness data.","FDA review expected within 6 months of acceptance; acknowledgment in 30 days.","Reproxalap showed acute activity in reducing dry eye symptoms and ocular redness in trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":105561870.76023392,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188698,"accession_number":"0001193125-24-231158","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","form_type":"8-K","filed_at":"2024-10-02T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Aldeyra extends Hercules loan maturity to April 2026; interest rate floor 11.10%","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Fourth Amendment extends interest-only period to April 1, 2026 and maturity to same date.","Outstanding $15M term loan; interest rate increased to Prime + 3.10% (floor 11.10%).","New $300K end-of-term charge payable at maturity or prepayment.","No other changes to loan covenants or collateral; reaffirms existing security interests."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":105561870.76023392,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205169,"accession_number":"0001193125-24-211645","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","form_type":"8-K","filed_at":"2024-09-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Aldeyra appoints Michael Alfieri as principal financial officer, Bruce Greenberg steps down","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Alfieri appointed as principal financial officer and principal accounting officer, effective Aug 31, 2024, via consulting agreement with Danforth Global, Inc.","Bruce Greenberg stepped down from positions including SVP Finance, Interim CFO, and principal accounting officer as of Aug 31, 2024.","Greenberg receives separation: six months base salary, lump-sum $125,895, and COBRA premium payments for up to six months.","Greenberg will provide consulting services through Nov 30, 2024, with continued vesting of outstanding stock options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":105561870.76023392,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205168,"accession_number":"0001213900-24-066327","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Aldeyra achieves primary endpoint in Phase 3 dry eye trial of reproxalap; NDA resubmission planned 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint of ocular discomfort met (p=0.004) vs vehicle in 132-patient Phase 3 dry eye chamber trial.","NDA resubmission for reproxalap anticipated in 2024; FDA review period expected ~6 months.","Reproxalap studied in over 2,500 patients; no safety signals; mild transient instillation site discomfort most common AE.","Option agreement with AbbVie includes $100M upfront if exercised, plus up to $300M milestones and profit/loss share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":105561870.76023392,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205167,"accession_number":"0001193125-24-191518","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Aldeyra Therapeutics enters into $75M at-the-market equity offering with Jefferies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New Open Market Sale Agreement with Jefferies LLC to sell up to $75M of common stock.","Prior $100M sales agreement terminated; no sales made under prior agreement.","Agent compensation: up to 3% of gross sales price; Company may designate minimum price.","Company has no obligation to sell any shares; agreement can be terminated by either party."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":105561870.76023392,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222048,"accession_number":"0001213900-24-054003","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aldeyra advances new RASP modulators ADX-743, ADX-248, ADX-631; pediatric ADX-629 top-line results expected 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ADX-629 advanced to pediatric cohort in Sjögren-Larsson Syndrome Phase 2; top-line results from ~5 patients expected 2025.","Novel RASP modulator ADX-743 entered IND-enabling studies for obesity; IND submission planned 2025.","ADX-248 selected over ADX-246 for Phase 1/2 in atopic dermatitis; Phase 1 to start H2 2024.","ADX-631 initiated preclinical testing in retinal disease; IND submission for dry AMD/geographic atrophy expected H1 2025.","Investor roundtable webcast June 20, 2024 at 8:00 am ET to discuss these pipeline updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":105561870.76023392,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222047,"accession_number":"0001213900-24-052234","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aldeyra completes enrollment in Phase 3 dry eye trial of reproxalap; results expected in Q3 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 dry eye chamber trial of 0.25% reproxalap enrolled 132 patients; primary endpoint is ocular discomfort.","Topline results expected in Q3 2024; NDA resubmission planned for H2 2024 contingent on positive data.","If approved, reproxalap may be first dry eye drug labeling chronic/acute symptom improvement and ocular redness reduction.","Four prior chamber trials showed reproxalap statistically superior to vehicle on ocular discomfort (p=0.0003)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":105561870.76023392,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222046,"accession_number":"0001193125-24-157328","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Aldeyra annual meeting results: directors elected, auditor ratified, say-on-pay approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Directors Nancy B. Miller-Rich (21.9M for, 12.6M withheld) and Ben R. Bronstein (22.7M for, 11.8M withheld) elected as Class I directors.","Shareholders ratified BDO USA as independent auditor for FY 2024: 44.1M for, 372.8K against, 186.6K abstain.","Non-binding advisory vote on named executive officer compensation approved: 31.5M for, 2.9M against, 126.6K abstain, 10.2M broker non-votes.","Total shares voted: 44,659,863 of 59,414,489 eligible (75.2% quorum)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":105561870.76023392,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222045,"accession_number":"0001213900-24-035953","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","form_type":"8-K","filed_at":"2024-04-25T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Aldeyra R&D Day: reproxalap NDA resubmission H2 2024; positive preclinical data for ADX-246, ADX-629","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reproxalap NDA resubmission expected H2 2024, pending Phase 3 dry eye chamber trial results and FDA discussions.","ADX-629 showed statistically significant improvement in EASI, itching, and POEM scores in Phase 2 atopic dermatitis trial.","ADX-246 reduced hepatic acetaldehyde, histopathology, and liver enzymes in preclinical alcoholic hepatitis model.","ADX-629 enhanced GLP-1-mediated weight and fat mass loss in a diet-induced obesity mouse model.","Next-generation RASP modulators ADX-248 and ADX-246 demonstrated broad activity in preclinical inflammation models."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":105561870.76023392,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241579,"accession_number":"0001213900-24-026871","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aldeyra plans reproxalap NDA resubmission for dry eye disease in H2 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Dry eye chamber trial to start H1 2024; NDA resubmission expected H2 2024 if positive.","FDA review period expected to be six months for potential resubmission.","Cash $142.8M as of Dec 31, 2023; projected to fund operations beyond 2026.","Primary endpoint: ocular discomfort; trial design from four prior reproxalap chamber trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":105561870.76023392,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241578,"accession_number":"0001157523-24-000230","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","form_type":"8-K","filed_at":"2024-02-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aldeyra Therapeutics presents at Oppenheimer Healthcare Conference; no material new financial data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["CEO Todd Brady participates virtually in fireside chat at Oppenheimer 34th Annual Healthcare Life Sciences Conference on Feb 13, 2024.","Discussion covers clinical and regulatory status of Aldeyra's product candidates for immune-mediated diseases.","Corporate presentation furnished as Exhibit 99.1; no earnings or financial guidance provided.","Filing is Regulation FD disclosure; presentation not incorporated by reference.","No specific milestones, data readouts, or financial results announced in the exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":105561870.76023392,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241577,"accession_number":"0001157523-24-000014","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","form_type":"8-K","filed_at":"2024-01-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aldeyra advances RASP modulator pipeline; multiple IND submissions and trial initiations planned for 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Positive biomarker results from ADX-629 in Sjögren-Larsson Syndrome adult cohort; pediatric expansion submission expected H1 2024.","Phase 2 trial of ADX-629 in moderate alcoholic hepatitis initiated; top-line results expected H2 2024.","IND for ADX-246 submitted for phase 1 in healthy volunteers; expected to expand to atopic dermatitis patients; top-line results H2 2024.","IND for ADX-248 expected in 2024 for phase 1/2 in dry AMD with dark adaptation deficit.","De-prioritized ADX-629 in chronic cough and idiopathic nephrotic syndrome; new preclinical RASP modulator program in metabolic disease initiated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":105561870.76023392,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259025,"accession_number":"0001193125-23-301185","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","form_type":"8-K","filed_at":"2023-12-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"AbbVie extends option for Aldeyra's reproxalap with $5M fee","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AbbVie paid $5M non-refundable fee to extend option period for reproxalap co-development license.","Exercise period now until 10 business days after FDA approval or 18 months from Oct 31, 2023.","Option fee will be credited against upfront cash if License Agreement is signed.","Reproxalap is Aldeyra's NDA-stage treatment for dry eye disease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":105561870.76023392,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259024,"accession_number":"0001157523-23-001841","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","form_type":"8-K","filed_at":"2023-12-19T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Aldeyra announces positive Phase 2 data for ADX-629 in atopic dermatitis; advancing ADX-246","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 trial of ADX-629 in 8 mild-to-moderate atopic dermatitis patients showed statistically significant improvement from baseline in EASI (p=0.0006) and IGA (p<0.0001).","Three patients (38%) achieved EASI-75; one patient (13%) had complete clearance of affected body surface area; two patients (25%) reported elimination of itching.","Only two mild treatment-related adverse events reported; no serious adverse events or discontinuations. All eight patients completed the trial.","Company plans to initiate a randomized placebo-controlled Phase 1/2 trial of ADX-246 in H1 2024, with topline results expected in H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":105561870.76023392,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259023,"accession_number":"0001193125-23-283679","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","form_type":"8-K","filed_at":"2023-11-28T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA issues Complete Response Letter for reproxalap NDA in dry eye disease; additional trial required","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA CRL states NDA did not demonstrate efficacy on ocular symptoms; requires at least one additional adequate and well-controlled study.","No safety or manufacturing issues identified.","Aldeyra submitted SPA for chamber crossover trial on Nov 16; expects FDA feedback in Dec 2023.","Proposed trial cost <$2M, top-line results expected H1 2024; potential NDA resubmission in H1 2024.","Cash runway extended to late 2025, with $143M cash as of Sep 30, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":105561870.76023392,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259022,"accession_number":"0001193125-23-267697","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","form_type":"8-K","filed_at":"2023-11-01T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Aldeyra grants AbbVie exclusive option to co-develop reproxalap; $1M upfront, $100M upon exercise","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AbbVie pays $1M non-refundable option fee; can extend option for $5M if FDA decision delayed past Dec 15, 2023.","Upon exercise, AbbVie pays $100M upfront (less prior payments); Aldeyra eligible for up to ~$300M in regulatory and commercial milestones.","In the US, profits/losses split 60% AbbVie, 40% Aldeyra; outside US, Aldeyra receives tiered royalties on net sales.","AbbVie gets right of first negotiation on Aldeyra's other ocular surface compounds and data review rights.","Option expires Dec 23, 2023 if not exercised or extended; tied to FDA decision on reproxalap NDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":105561870.76023392,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259021,"accession_number":"0001193125-23-256532","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","form_type":"8-K","filed_at":"2023-10-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Aldeyra: FDA may not approve reproxalap NDA by Nov 23 PDUFA; additional trial needed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA late-cycle review states reproxalap lacks data to support clinical relevance of ocular signs for dry eye.","FDA indicated Aldeyra needs to conduct an additional clinical trial to satisfy efficacy requirements.","Based on review timeline, FDA may issue Complete Response Letter and not approve by Nov 23, 2023 PDUFA date.","Aldeyra submitted responses to mitigate issues, but FDA has not opined on sufficiency and has no obligation to review.","Reproxalap NDA accepted in Feb 2023; approval now uncertain, requiring more resources and time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":105561870.76023392,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276312,"accession_number":"0001193125-23-181344","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","form_type":"8-K","filed_at":"2023-07-03T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Aldeyra shareholders elect Brady and Joyce as Class III directors, approve 2023 equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Director Todd C. Brady reelected with 21,007,679 votes for, 7,405,955 withheld.","Director Martin J. Joyce elected with 16,126,225 votes for, 12,287,409 withheld.","Ratification of BDO USA as auditor approved: 43,474,045 for, 25,820 against.","Advisory vote on executive compensation approved: 27,710,251 for, 57,323 abstain.","2023 Equity Incentive Plan approved: 27,066,030 for, 1,293,014 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":105561870.76023392,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293998,"accession_number":"0001157523-23-001047","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","form_type":"8-K","filed_at":"2023-06-29T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Aldeyra reports positive Phase 2 data for ADX-2191 in retinitis pigmentosa","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Statistically significant improvement in best corrected visual acuity (P<0.0001) and low-light visual acuity (P=0.0001).","Perimetry showed improved macular sensitivity (P<0.0001) and dark-adapted peripheral sensitivity (P<0.0001).","Electroretinography time to response improved (P=0.02); no safety concerns identified.","All 8 patients completed trial; ADX-2191 well tolerated with no serious adverse events.","Company plans to discuss Phase 2/3 trial design with regulatory authorities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":105561870.76023392,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293997,"accession_number":"0001157523-23-001035","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","form_type":"8-K","filed_at":"2023-06-27T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Aldeyra Phase 2 ADX-629 in chronic cough meets primary safety endpoint; cough frequency significantly reduced vs placebo","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Awake cough frequency reduced vs placebo (P=0.01); 24-hr cough frequency (P=0.001).","ADX-629 well tolerated; no serious adverse events or discontinuations reported.","51 patients enrolled, all completed both treatment periods in crossover design.","Improvement in LDL and HDL levels observed consistent with prior trials.","Company to discuss results with regulators; Phase 2 trials in atopic dermatitis and other indications expected 2H 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":105561870.76023392,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293996,"accession_number":"0001157523-23-001018","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","form_type":"8-K","filed_at":"2023-06-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA issues Complete Response Letter for Aldeyra's ADX-2191 NDA for PVRL","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cited lack of substantial evidence due to no adequate well-controlled studies in literature-based NDA.","No safety or manufacturing issues identified in the Complete Response Letter.","Aldeyra plans Expanded Access Program discussions with FDA due to methotrexate shortage and no approved PVRL therapy.","ADX-2191 also under development for proliferative vitreoretinopathy and retinitis pigmentosa.","Top-line Phase 2 results in retinitis pigmentosa expected to be announced June 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":105561870.76023392,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293995,"accession_number":"0001157523-23-000973","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","form_type":"8-K","filed_at":"2023-06-15T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Aldeyra announces positive Phase 3 INVIGORATE-2 trial for reproxalap in allergic conjunctivitis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint met: ocular itching reduction at all 11 timepoints (p<0.0001).","Key secondary endpoint ocular redness achieved (p=0.004); tearing and total severity score also significant (p<0.0001).","Results consistent with prior trials; no safety concerns; 130 of 131 patients completed.","Reproxalap NDA for dry eye disease under FDA review with PDUFA date of November 23, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":105561870.76023392,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293994,"accession_number":"0001157523-23-000722","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Aldeyra Q1 net loss $15.6M; PDUFA dates set; clinical readouts in Q2 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $15.6M ($0.27 loss per share) vs $16.8M ($0.29) in Q1 2022.","Cash and equivalents $165.0M; projected runway into H2 2024.","PDUFA dates: ADX-2191 (June 21, 2023) for vitreoretinal lymphoma; reproxalap (Nov 23, 2023) for dry eye.","Top-line Q2 2023: Phase 2 ADX-2191 (retinitis pigmentosa), Phase 2 ADX-629 (chronic cough), Phase 3 INVIGORATE-2 (allergic conjunctivitis).","Aldeyra will discontinue quarterly earnings conference calls, citing shift to clinical/regulatory updates."],"consensus_eps_estimate":null,"consensus_eps_actual":0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":105561870.76023392,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314608,"accession_number":"0001193125-23-067701","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Aldeyra Therapeutics discloses no exposure to Silicon Valley Bank","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company confirms it holds no cash deposits or securities with Silicon Valley Bank.","Aldeyra has no business relationship with Silicon Valley Bank.","Disclosure made on March 10, 2023, amid SVB's collapse that day."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":105561870.76023392,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314607,"accession_number":"0001157523-23-000419","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","form_type":"8-K","filed_at":"2023-03-09T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Aldeyra posts FY2022 net loss $62.0M, cash $174.3M; two NDAs under FDA review with PDUFA dates June and Nov 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $62.0M ($1.06/share) vs $57.8M ($1.07/share) in 2021; R&D $47.3M, G&A $15.4M.","Cash $174.3M at Dec 31, 2022; runway into H2 2024, covering launch preparations if approved.","FDA Priority Review for ADX-2191 (vitreoretinal lymphoma) with PDUFA June 21, 2023; no filing issues identified.","FDA accepted NDA for reproxalap (dry eye disease) with PDUFA Nov 23, 2023; no advisory committee planned.","Upcoming: Phase 3 INVIGORATE-2 allergic conjunctivitis, Phase 2 ADX-2191 RP, Phase 2 ADX-629 cough results expected H1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":105561870.76023392,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314606,"accession_number":"0001157523-23-000387","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","form_type":"8-K","filed_at":"2023-03-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA accepts Aldeyra's NDA for ADX-2191 with Priority Review; PDUFA June 21, 2023","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted NDA for ADX-2191 (methotrexate injection) for primary vitreoretinal lymphoma with Priority Review.","PDUFA date set for June 21, 2023; FDA noted no potential filing review issues identified.","Planned U.S. launch in second half of 2023, pending FDA approval.","NDA supported by over 30 years of published literature and safety data from Phase 3 GUARD Trial.","ADX-2191 has potential to be first FDA-approved drug for primary vitreoretinal lymphoma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":105561870.76023392,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}